Drug General Information
Drug ID	D01BVI
Former ID	DIB016550
Drug Name	V-101
Drug Type	Small molecular drug
Indication	Erythema [ICD9: 695; ICD10:L51-L54]		Phase 2	[523141]
Company	Vicept Therapeutics Inc
Structure		Download 2D MOL 3D MOL
Formula	C12H6Cl4S
Canonical SMILES	C1=CC(=CC=C1SC2=CC(=C(C=C2Cl)Cl)Cl)Cl
InChI	1S/C12H6Cl4S/c13-7-1-3-8(4-2-7)17-12-6-10(15)9(14)5-11(12)16/h1-6H
InChIKey	QUWSDLYBOVGOCW-UHFFFAOYSA-N
PubChem Compound ID	16685
PubChem Substance ID	6117681, 8162500, 24862557, 29217921, 29284519, 48413449, 49857254, 57329472, 57649564, 75227897, 104340503, 124489704, 124893233, 126409829, 129078622, 134983333, 137012811, 144209590, 144213301, 162252226, 164817940, 165373836, 176263564, 184583685, 198976120, 223447082, 223518516, 226414346, 241238158, 242176395, 250101386, 252329535
Target and Pathway
Target(s)	Alpha-2C adrenergic receptor	Target Info	Agonist	[532145]
KEGG Pathway	cGMP-PKG signaling pathway
	Neuroactive ligand-receptor interaction
PANTHER Pathway	Alpha adrenergic receptor signaling pathway
	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Reactome	Adrenoceptors
	Adrenaline signalling through Alpha-2 adrenergic receptor
	Adrenaline,noradrenaline inhibits insulin secretion
	G alpha (i) signalling events
	G alpha (z) signalling events
	Surfactant metabolism
WikiPathways	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	Platelet Aggregation (Plug Formation)
	Integration of energy metabolism
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 523141	ClinicalTrials.gov (NCT01186068) Dose Response Study of Patients With Erythematous Rosacea. U.S. National Institutes of Health.
Ref 532145	Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012 Dec;17(10):1-4.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.